Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide for Microvascular Dysfunction in Type 1 Diabetes
NCT05478707Phase 2Recruiting
- Sponsor
- AdventHealth Translational Research Institute
- Start
- Oct 2023
- Primary completion
- Jun 2028
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised trial of dulaglutide biosimilar 14028 injection in type 1 diabetes mellitus (T1D) and endothelial dysfunction (2 arms), sponsored by AdventHealth Translational Research Institute. Primary endpoint: Microvascular blood volume at 14 weeks. Started Oct 2023; status: recruiting.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
type 1 diabetes mellitus (T1D)endothelial dysfunction
Beyond the preview
Go deeper on NCT05478707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05478707.